

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5139903

|   |                              |
|---|------------------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT               |
| <b>NATURE OF CONVEYANCE:</b>  | PATENT RELEASE               |
| <b>CONVEYING PARTY DATA</b>   |                              |
| <b>Name</b>   | <b>Execution Date</b>        |
| AVENTIS INC.  | 09/13/2018                   |
| <b>RECEIVING PARTY DATA</b>   |                              |
| <b>Name:</b>  | PROTEIN SCIENCES CORPORATION |
| <b>Street Address:</b>  | 1000 RESEARCH PARKWAY        |
| <b>City:</b>  | MERIDEN                      |
| <b>State/Country:</b>   | CONNECTICUT                  |
| <b>Postal Code:</b>   | 06450                        |
| <b>PROPERTY NUMBERS Total: 6</b>  |                              |
| <b>Property Type</b>  | <b>Number</b>                |
| Patent Number:  | 6224882                      |
| Patent Number:  | 6103526                      |
| PCT Number:   | US2014025837                 |
| Patent Number:  | 7598075                      |
| Patent Number:  | 7879601                      |
| Patent Number:  | 8541003                      |
| <b>CORRESPONDENCE DATA</b>  |                              |
| <b>Fax Number:</b>  | (212)310-8007                |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                              |
| <b>Phone:</b>   | 212.310.8000                 |
| <b>Email:</b>   | juan.arias@weil.com          |
| <b>Correspondent Name:</b>  | CHRISTINA O'CONNELL          |
| <b>Address Line 1:</b>  | WEIL, GOTSHAL & MANGES LLP   |
| <b>Address Line 2:</b>  | 767 FIFTH AVENUE             |
| <b>Address Line 4:</b>  | NEW YORK, NEW YORK 10153     |
| <b>NAME OF SUBMITTER:</b>   | CHRISTINA O'CONNELL          |
| <b>SIGNATURE:</b>   | /CHRISTINA O'CONNELL/        |
| <b>DATE SIGNED:</b>   | 09/13/2018                   |
| <b>Total Attachments: 3</b>   |                              |

source=Sanofi - IP Release (Patent)#page1.tif

source=Sanofi - IP Release (Patent)#page2.tif

source=Sanofi - IP Release (Patent)#page3.tif

**PATENT RELEASE**

THIS PATENT RELEASE (this “**Patent Release**”) is made as of September 13, 2018, by Aventis Inc., as Parent under the Patent Security Agreement referred to below (in such capacities, the “**Parent**”). Capitalized terms used but not defined herein shall have the same meanings assigned to such terms in the that certain Promissory Note, dated as of July 21, 2017 (the “**Promissory Note**”) by and among the Grantor (as defined below) and the Parent.

WHEREAS, pursuant to that certain Patent Security Agreement, dated as of July 21, 2017 (the “**Patent Security Agreement**”), by Protein Sciences Corporation (the “**Grantor**”), in favor of the Parent, which was recorded with the Patent Division of the United States Patent and Trademark Office, at Reel 043292, Frame 0358 on July 21, 2017, the Grantor granted to the Parent, for its benefit, a lien on and security interest in such Grantor’s right, title and interest in and to the Patent registrations, applications for Patent registration, in each case to the extent constituting Collateral, including, without limitation, the items listed on Schedule 1 hereto, and all proceeds of the foregoing to the extent constituting Collateral (the “**IP Collateral**”).


NOW, THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, the Parent does hereby agree as follows:

1. The Parent hereby (i) terminates the Patent Security Agreement and any and all rights it may have under the Patent Security Agreement, (ii) terminates, cancels, releases and discharges its entire Lien on and security interest in the Grantor’s right, title and interest in, to and under the IP Collateral, and (iii) authorizes the recordation of this Patent Release with the United States Patent and Trademark Office.
2. The Parent hereby reassigns, grants and conveys to the Grantor, without any representation, recourse or undertaking by the Parent, any and all of the Parent’s right, title and interest in, to and under the IP Collateral, and the Parent hereby releases, terminates and cancels any mortgage, pledge or hypothecate made by the Grantor to the Parent pursuant to the Patent Security Agreement.
3. The Parent hereby agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts as may be necessary to effect the release of the security interest contemplated hereby, in each case, at the Grantor’s sole expense.
4. This Patent Release shall be governed by, and construed and interpreted in accordance with, the law of the State of New York without regard to conflict of laws principles that would result in the application of any other law other than the law of the State of New York.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the Parent has caused this Patent Release to be executed as of the day and year first above written.

AVENTIS INC.

By:   
Name: Douglas J. McCormack  
Title: Vice President

# SCHEDULE 1

## PATENTS

| Grantor                      | Title  | Patent No. | Expiration Date | Appl. Ser. No.   |
|------------------------------|--|------------|-----------------|------------------|
| Protein Sciences Corporation | INSECT CELLS OR FRACTIONS AS ADJUVANT FOR ANTIGENS   | 6,224,882  | 11/7/2017       | 08/965,698       |
| Protein Sciences Corporation | SPODOPTERA FRUGIPERDA SINGLE CELL SUSPENSION CELL LINE IN SERUM-FREE MEDIA, METHODS OF PRODUCING AND USING                                       | 6,103,526  | 10/8/2018       | 09/169,178       |
| Protein Sciences Corporation | METHOD FOR PRODUCING INFLUENZA HEMAGGLUTININ MULTIVALENT VACCINES USING BACULOVIRUS  | 5,762,939  | 6/9/2020        | 08/120,607       |
| Protein Sciences Corporation | IMPROVED STABILITY AND POTENCY OF HEMAGGLUTININ  |            |                 | PCT/US2014/25837 |
| Protein Sciences Corporation | APPARATUS AND METHODS FOR PRODUCING AND USING HIGH-DENSITY CELLS AND PRODUCTS THEREFROM  | 7,598,075  | 4/16/2021       | 11/097,994       |
| Protein Sciences Corporation | APPARATUS AND METHODS FOR PRODUCING AND USING HIGH-DENSITY CELLS AND PRODUCTS THEREFROM  | 7,879,601  | 1/18/2020       | 12/573,468       |
| Protein Sciences Corporation | VECTORS EXPRESSING SARS IMMUNOGENS, COMPOSITIONS CONTAINING SUCH VECTORS OR EXPRESSION PRODUCTS THEREOF, METHODS AND ASSAYS FOR MAKING AND USING | 8,541,003  | 6/4/2026        | 10/873,424       |
| Protein Sciences Corporation | VECTORS EXPRESSING SARS IMMUNOGENS, COMPOSITIONS CONTAINING SUCH VECTORS OR EXPRESSION PRODUCTS THEREOF, METHODS AND ASSAYS FOR MAKING AND USING | 4750024    | 6/21/2024       | 2006-517653      |